Company profile
Neurogene Inc.
NASDAQ:NGNEBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05898620 | phase3 | active_not_recruiting | 2023-06-13 | 2029-12-01 | Neurogene Inc. | A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome |
| NCT05228145 | phase1_2 | active_not_recruiting | 2022-01-31 | 2028-11-01 | Neurogene Inc. | Gene Therapy Study for Children With CLN5 Batten Disease |
| NCT04659629 | phase1 | completed | 2021-04-26 | 2022-12-15 | Neurogene Inc. | NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer |
FDA applications (0)
No records yet.